Flow cytometry analysis of MHCII (I-Ab) expression further showed that although the proportions of microglia (CD45medCD11b+), tumor-infiltrating myeloid cells (CD45hiCD11b+), macrophages (CD45hiCD11b+Gr-1−F4/80+), dendritic cells (DCs) (CD45hiCD11c+MHCII+), CD45hiCD11c+ MHCII+CD11b+ DC subset and their MHCII-expressing populations were largely not significantly changed (except MHCII+ myeloid cells at day 21 post-treatment), the MHCII expression levels were significantly upregulated in myeloid cells, macrophages and DCs (Supplementary Fig. 2a–g). The gene discussed is ITGAM; the disease is neoplasm.